• Capstone Therapeutics forecast positive Adjusted EBITDA for Q2 2026 following integration gains from recent acquisitions.
• Converted $700,000 of surplus inventory into full-margin sales within six months of the Canadian Stone Industries deal.
• Integration platform redeployed inventory to higher-demand markets, supporting working-capital efficiency and margin expansion.
• Midwest distribution network consolidation in May targeted $500,000 in annualized cost savings, unlocking $700,000 of working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607140730BIZWIRE_USPR_____20260714_BW176416) on July 14, 2026, and is solely responsible for the information contained therein.